Family MemberNCT02019628
Enhanced Natural Killer Cell Activity and RBAC
A study testing Rice Bran Arabinoxylan Compound (RBAC) in people with Family Member, run by University of Miami at 1 site in United States.
Trial summary
The present study investigated the effect of RBAC on natural killer cell activity (NKCA) and the production of cytokines and growth factors over 4 weeks among healthy adults. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Family Member
- What is being tested?
- Rice Bran Arabinoxylan Compound (RBAC)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2009to Nov 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women and men ages 18 years and over.
- Interest in participating in a novel nutritional supplement program.
- Willingness to follow recommendations.
Who cannot join
- Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.
- Unable to consent to the study.
- Women who are pregnant or are attempting conception, especially in the presence of a history of recurrent spontaneous abortion.
- Other medical complications that might preclude one from participating in the study, i.e., recent heart attack or stroke or chronic kidney disease.
- Currently taking immunomodulatory medication, i.e. interferon.
- Currently taking other medications thought to have an impact on immune system functioning, i.e., chemotherapeutic agents.
Show all 10Show fewer
- Known allergy to rice, rice bran, or related food products.
- Known allergy to mushrooms or related food products.
- History of malignancies related to the NK cell line, including: NK cell leukemias and T-cell large granular lymphocyte leukemias, NK-cell lymphoproliferative disease of granular lymphocytes, and NK cell lymphomas, e.g., nasal and nasal-like NK/T-cell lymphomas.
- Current smoker.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Enhancement of Natural Killer Cell Activity in Healthy Adults by Rice Bran Arabinoxylan Compound, a Novel Oligosaccharide
The present study investigated the effect of RBAC on natural killer cell activity (NKCA) and the production of cytokines and growth factors over 4 weeks among healthy adults.
Read the detailed description
The purpose of this study is to investigate the outcomes of a 60-day trial of Rice Bran Arabinoxylan Compound (RBAC) among adults. Specifically, subjects will participate in a two-group, randomized intervention that is based on a nutritional supplement made from a water soluble extract of rice bran that has been partially hydrolyzed by the action of a natural enzyme complex extracted from Shitake mushroom. One group will take 1 gram/day and the other group will take 3 gram/day to compare differences in outcomes between the two groups. We hypothesize that the 3 gram/day condition will demonstrate faster increases in outcomes compared to the 1 gram/day condition. The primary outcomes for this study will be Natural Killer (NK) cell activity, cytokines, total bilirubin, creatinine, and liver function tests. These outcomes will be compared between those subjects enrolled in the two treatment groups before and after 60 days.
No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture. Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.
The components of RBAC should be harmless without significant food allergies. No serious, untoward side effects have been reported to the company by consumers nor observed during previous human studies. If any side effect does occur, the remedy is to discontinue until asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2 days, if uneventful, until full dosage is achieved. Dr. Ali will provide additional follow-up and consultation with any subject who experiences an untoward side effect.
A toxicology search for each component reveals no unique toxicity characteristic of the materials. As reported by Daiwa Health Development, the manufacturer of the product, thousands of people currently use RBAC (under the trade names BRM4 and PeakImmune 4), and Daiwa is unaware of significant toxicities. Daiwa applies the latest scientific methods to ensure the value and safety of their raw materials. Daiwa products are manufactured in state-of-the-art facilities, under strict quality control and environmental protection standards.
Participants will incur no additional appreciable psychological or social risks by participating in this study, although they may undergo psychological and physical discomfort sometimes. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.
Alternatives to this study for enhancing immune system functioning include prescription medications, exercise, dietary modification, and other nutritional supplements. The risks of medications can be very significant, including life-threatening, but the risk of taking nutritional supplements is not totally understood, since they are not regulated by the US Food and Drug Administration. Medications and nutritional supplements, as part of a change in lifestyle behaviors, may also prove to be beneficial for immune system functioning, but their long-term use has unknown consequences.
The information obtained in this study will help in determining the efficacy of using a rice bran extract nutritional supplement for enhancing immune system outcomes. By participating in the study, subjects may experience improved NK cell activity and cytokine functioning. The risk of participating in this study is reasonable because of the potential enhancements in immune system functioning with improved nutritional status.
- Conditions
- Family Member
- Being tested
- Rice Bran Arabinoxylan Compound (RBAC)
- Keywords
- NK cells cytotoxicity, dietary supplementation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rice Bran Arabinoxylan Compound (RBAC)Dietary supplement
Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
| Study group | Role | What they receive |
|---|---|---|
| BRM4 at a dosage level of 1 gram/day | Experimental | 60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day. Receives: Dietary Supplement: Rice Bran Arabinoxylan Compound (RBAC) |
| BRM4 at a dosage level of 3 grams/day | Experimental | 60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day. Receives: Dietary Supplement: Rice Bran Arabinoxylan Compound (RBAC) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Immune Functioning - NK Cell activity
NK Cell activity at baseline, 48 hours, 1 week, 1 month, and 2 months.
Measured: 60 days
Immune Functioning - Cytokines
Cytokines at baseline, 1 month, and 2 months.
Measured: 60 days
Secondary outcomes (9)
Bilirubin
Bilirubin at baseline, 48 hours, 1 week, 1 month, and 2 months.
Measured: 60 days
Blood Pressure and Heart Rate
Blood pressure and heart rate at baseline and 2 months.
Measured: 60 days
Physical Activity
Physical activity will be assessed at baseline and 2-months follow-up by the Stanford 7-day Activity Recall. This instrument assesses the amount (number of hours) of moderate, physically challenging, and very physically challenging activities over the past 7 days. This instrument provides useful estimates of habitual physical activity for research, significantly agrees with daily self-report of physical activity, and has been validated for use in community settings.
Measured: 60 days
Functional Health and Well-being
The SF-36v2™ Health Survey provides psychometrically-based physical and mental health summary measures and a preference-based health utility index. It is a generic measure that does not target a specific age, disease, or treatment group and will be assessed at baseline and 2-months follow-up.
Measured: 60 days
Creatinine
Creatinine at baseline, 48 hours, 1 week, 1 month, and 2 months.
Measured: 60 days
Liver Function Tests
Liver Function Tests at baseline, 48 hours, 1 week, 1 month, and 2 months.
Measured: 60 days
Body Mass Index
Body weight and height to calculate body mass index (BMI) at baseline and 2 months.
Measured: 60 days
Percent Body Fat
Skinfold caliper assessment to calculate percent body fat at baseline and 2 months.
Measured: 60 days
Waist to Hip Ratio
Waist and hip circumference to calculate waist to hip ratio at baseline and 2 months.
Measured: 60 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2013 (estimated)
- Study startNov 2009
- Primary completionApr 2011
- Study completionNov 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Family MemberStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Miami
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, John E. Lewis, University of Miami
- Investigators
- John E. Lewis, Ph.D., Principal investigator, University of Miami
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02019628
- Sponsor's protocol ID
- 20090384
- Status last verified
- Oct 2023
- First submitted
- 18 Dec 2013
- Last updated
- 10 Oct 2023
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Enhancement of Natural Killer Cell Activity in Healthy Adults by Rice Bran Arabinoxylan Compound, a Novel Oligosaccharide
- ClinicalTrials.gov ID
- NCT02019628
- Acronym / sponsor ID
- 20090384
- Conditions
- Family Member
- Keywords
- NK cells cytotoxicity, dietary supplementation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University of MiamiUniversity, hospital or other
- Study start
- Nov 2009
- Primary completion
- Apr 2011 (actual)
- Study completion
- Nov 2011 (actual)
- First posted
- 24 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study investigated the effect of RBAC on natural killer cell activity (NKCA) and the production of cytokines and growth factors over 4 weeks among healthy adults.
Detailed description
The purpose of this study is to investigate the outcomes of a 60-day trial of Rice Bran Arabinoxylan Compound (RBAC) among adults. Specifically, subjects will participate in a two-group, randomized intervention that is based on a nutritional supplement made from a water soluble extract of rice bran that has been partially hydrolyzed by the action of a natural enzyme complex extracted from Shitake mushroom. One group will take 1 gram/day and the other group will take 3 gram/day to compare differences in outcomes between the two groups. We hypothesize that the 3 gram/day condition will demonstrate faster increases in outcomes compared to the 1 gram/day condition. The primary outcomes for this study will be Natural Killer (NK) cell activity, cytokines, total bilirubin, creatinine, and liver function tests. These outcomes will be compared between those subjects enrolled in the two treatment groups before and after 60 days.
No substantial psychological, medical, or social risks exist to the participants, other than minor discomfort associated with the venipuncture. Although all measures to protect confidentiality will be put in place, the possibility exists that electronic data could be jeopardized. In the remote case that such event occurs, it will be immediately reported to the IRB.
The components of RBAC should be harmless without significant food allergies. No serious, untoward side effects have been reported to the company by consumers nor observed during previous human studies. If any side effect does occur, the remedy is to discontinue until asymptomatic, and then reintroduce at 1/4 dosage, increasing by the same amount every 2 days, if uneventful, until full dosage is achieved. Dr. Ali will provide additional follow-up and consultation with any subject who experiences an untoward side effect.
A toxicology search for each component reveals no unique toxicity characteristic of the materials. As reported by Daiwa Health Development, the manufacturer of the product, thousands of people currently use RBAC (under the trade names BRM4 and PeakImmune 4), and Daiwa is unaware of significant toxicities. Daiwa applies the latest scientific methods to ensure the value and safety of their raw materials. Daiwa products are manufactured in state-of-the-art facilities, under strict quality control and environmental protection standards.
Participants will incur no additional appreciable psychological or social risks by participating in this study, although they may undergo psychological and physical discomfort sometimes. The process of interviewing during the assessment may cause discomfort. Discomfort or fatigue may also be experienced in completing the assessment battery.
Alternatives to this study for enhancing immune system functioning include prescription medications, exercise, dietary modification, and other nutritional supplements. The risks of medications can be very significant, including life-threatening, but the risk of taking nutritional supplements is not totally understood, since they are not regulated by the US Food and Drug Administration. Medications and nutritional supplements, as part of a change in lifestyle behaviors, may also prove to be beneficial for immune system functioning, but their long-term use has unknown consequences.
The information obtained in this study will help in determining the efficacy of using a rice bran extract nutritional supplement for enhancing immune system outcomes. By participating in the study, subjects may experience improved NK cell activity and cytokine functioning. The risk of participating in this study is reasonable because of the potential enhancements in immune system functioning with improved nutritional status.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BRM4 at a dosage level of 1 gram/day | Experimental | Dietary Supplement: Rice Bran Arabinoxylan Compound (RBAC)60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day. |
| BRM4 at a dosage level of 3 grams/day | Experimental | Dietary Supplement: Rice Bran Arabinoxylan Compound (RBAC)60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Women and men ages 18 years and over.
- Interest in participating in a novel nutritional supplement program.
- Willingness to follow recommendations.
Key exclusion criteria (10 listed)
- Currently enrolled in another research trial for investigative nutritional or other therapies thought to have an impact on immune system functioning.
- Unable to consent to the study.
- Women who are pregnant or are attempting conception, especially in the presence of a history of recurrent spontaneous abortion.
- Other medical complications that might preclude one from participating in the study, i.e., recent heart attack or stroke or chronic kidney disease.
- Currently taking immunomodulatory medication, i.e. interferon.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rice Bran Arabinoxylan Compound (RBAC)Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate. | Dietary supplement | BRM4 at a dosage level of 1 gram/day, BRM4 at a dosage level of 3 grams/day |
Primary outcome
Immune Functioning - NK Cell activity
Time frame: 60 days
NK Cell activity at baseline, 48 hours, 1 week, 1 month, and 2 months.
Immune Functioning - Cytokines
Time frame: 60 days
Cytokines at baseline, 1 month, and 2 months.
9 secondary outcomes
Bilirubin
Time frame: 60 days
Blood Pressure and Heart Rate
Time frame: 60 days
Physical Activity
Time frame: 60 days
Functional Health and Well-being
Time frame: 60 days
Creatinine
Time frame: 60 days
Liver Function Tests
Time frame: 60 days
Body Mass Index
Time frame: 60 days
Percent Body Fat
Time frame: 60 days
Waist to Hip Ratio
Time frame: 60 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Oct 2023.
Related trials for Family Member
Not yet recruitingObservational study
SLAMF1 Gene Expression in Ankylosing Spondylitis
Ankylosing Spondylitis
Enrolling by invitationObservational study
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Neoplasms, Hematologic Neoplasms
Recruiting
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Psychotic Disorders, Family Members
Recruiting
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
Alcohol Abuse, Alcohol Use Disorder
Enrolling by invitationObservational study
Evaluation of a Voice-Activated Call Light System for Clients With Limited Upper-Extremity Mobility
Spinal Cord Injury (=3 Years), Traumatic Brain Injury (TBI) Patients
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John E. Lewis, Ph.D. principal investigator
University of Miami
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rice Bran Arabinoxylan Compound (RBAC) in people with Family Member, run by University of Miami at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Immune Functioning - NK Cell activity (time frame: 60 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Oct 2023.